CN102869360B - 治疗高血压的医药组合物及方法 - Google Patents

治疗高血压的医药组合物及方法 Download PDF

Info

Publication number
CN102869360B
CN102869360B CN201180022318.4A CN201180022318A CN102869360B CN 102869360 B CN102869360 B CN 102869360B CN 201180022318 A CN201180022318 A CN 201180022318A CN 102869360 B CN102869360 B CN 102869360B
Authority
CN
China
Prior art keywords
amlodipine
dextromethorphan
hypertension
blood pressure
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180022318.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102869360A (zh
Inventor
陈肇文
王锡杰
庄欣怡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsh Biopharm Co ltd
Original Assignee
Tsh Biopharm Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsh Biopharm Co ltd filed Critical Tsh Biopharm Co ltd
Publication of CN102869360A publication Critical patent/CN102869360A/zh
Application granted granted Critical
Publication of CN102869360B publication Critical patent/CN102869360B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180022318.4A 2010-05-03 2011-04-29 治疗高血压的医药组合物及方法 Expired - Fee Related CN102869360B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33054010P 2010-05-03 2010-05-03
US61/330,540 2010-05-03
PCT/CN2011/073560 WO2011137734A1 (en) 2010-05-03 2011-04-29 Pharmaceutical composition and method for treating hypertension

Publications (2)

Publication Number Publication Date
CN102869360A CN102869360A (zh) 2013-01-09
CN102869360B true CN102869360B (zh) 2015-03-25

Family

ID=44903590

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180022318.4A Expired - Fee Related CN102869360B (zh) 2010-05-03 2011-04-29 治疗高血压的医药组合物及方法

Country Status (11)

Country Link
US (2) US20130053411A1 (https=)
EP (1) EP2566478A4 (https=)
JP (1) JP5847162B2 (https=)
KR (1) KR20130061148A (https=)
CN (1) CN102869360B (https=)
AU (1) AU2011250485B2 (https=)
BR (1) BR112012028153A2 (https=)
MY (1) MY161853A (https=)
RU (1) RU2571284C2 (https=)
TW (1) TWI583383B (https=)
WO (1) WO2011137734A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6301371B2 (ja) * 2013-02-14 2018-04-11 ノバルティス アーゲー インビボ効力が改善されたｎｅｐ阻害剤としての置換ビスフェニルブタン酸誘導体
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
TW201717947A (zh) * 2015-08-20 2017-06-01 漢達生技醫藥股份有限公司 包含氨氯地平和右美沙芬的藥物組合物
MX2019006938A (es) 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
SI4101454T1 (sl) 2017-01-25 2024-10-30 The George Institute for Global Health Sestavki za uporabo pri zdravljenju hipertenzije
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023947A (zh) * 2006-02-24 2007-08-29 江传箕 用于杀菌、抑菌和抗炎的组合物及其方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676177A (en) 1949-11-09 1954-04-20 Hoffmann La Roche Process for the preparation of optically active 3-methoxy-n-methyl morphinans and salts thereof
GB8710493D0 (en) 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
WO1992003137A1 (en) * 1990-08-23 1992-03-05 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
JPH04368338A (ja) * 1991-06-12 1992-12-21 Taisho Pharmaceut Co Ltd 鎮咳剤
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5560913A (en) 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
CA2486157C (en) * 2002-05-17 2013-04-16 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
KR100476636B1 (ko) 2002-09-11 2005-03-17 한림제약(주) 엘-(+)-타르트레이트를 이용한 에스-(-)-암로디핀의 제조방법
CL2003002653A1 (es) * 2002-12-18 2005-04-22 Wyeth Corp Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
WO2006033965A2 (en) 2004-09-16 2006-03-30 The Trustees Of The University Of Pennsylvania Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US20060188450A1 (en) * 2005-02-24 2006-08-24 Tim Clarot System and method for suppressing a cough
US7820689B2 (en) 2006-08-10 2010-10-26 Hua-Lin Wu Methods and compositions for preventing or treating cardiovascular disease
US8569364B2 (en) * 2007-11-28 2013-10-29 Sequoia Pharmaceuticals, Inc. 5-substituted benzofurans as inhibitors of cytochrome P450 2D6

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023947A (zh) * 2006-02-24 2007-08-29 江传箕 用于杀菌、抑菌和抗炎的组合物及其方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
小胶质细胞与炎症介导的神经系统退行性病变;薛旸等;《生命科学》;20070228;第19卷(第1期);第43-46页 *
氧化应激在D5多巴胺受体基因敲除小鼠血压升高中的作用研究;杨志伟等;《中国比较医学杂志》;20060331;第16卷(第3期);第129-134页 *

Also Published As

Publication number Publication date
US20160235741A1 (en) 2016-08-18
MY161853A (en) 2017-05-15
CN102869360A (zh) 2013-01-09
JP2013525460A (ja) 2013-06-20
WO2011137734A1 (en) 2011-11-10
RU2571284C2 (ru) 2015-12-20
EP2566478A4 (en) 2014-04-30
KR20130061148A (ko) 2013-06-10
AU2011250485A1 (en) 2012-12-06
US20130053411A1 (en) 2013-02-28
EP2566478A1 (en) 2013-03-13
JP5847162B2 (ja) 2016-01-20
US9744165B2 (en) 2017-08-29
TWI583383B (zh) 2017-05-21
BR112012028153A2 (pt) 2018-08-07
RU2012151051A (ru) 2014-06-10
TW201206437A (en) 2012-02-16
AU2011250485B2 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
US9744165B2 (en) Method for treating hypertension
Wang et al. Tetrandrine: a new ligand to block voltage-dependent Ca2+ and Ca2+-activated K+ channels
HUT77315A (hu) Loratadinszármazék allergiás és egyéb betegségek kezelésében való alkalmazásra
CN101815438A (zh) 治疗依赖性的方法
KR20040032141A (ko) 제약 복합제제
CA2124445A1 (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
JP2007169278A (ja) Ｌｕｔｓ処置用の医薬組合せ
WO2019241020A1 (en) Serdexmethylphenidate conjugates, compositions and methods of use thereof
US20070032471A1 (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
NZ514552A (en) NR2B subunit selective N-methyl-D-aspartate (NMDA) receptor antagonists for treating or preventing neurological damage and pain
ES2847904T3 (es) Medicamento para la prevención o el tratamiento de la hipertensión
Guarneri et al. In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers
SG190326A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
JP2012532855A (ja) 医薬として使用するための組合せ製剤
JPS63310867A (ja) 抗鬱病剤作用を有する新規な結合生成物
US5571827A (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine
CN105924382B (zh) S-马尼地平盐酸盐i晶型及其制备方法
EP0965341A2 (en) Combination of dofetilide and a calcium channel blocker
TW201304775A (zh) 使用依普羅沙坦與氨氯地平治療高血壓的組成物和方法
WO2010047369A1 (ja) 糖尿病性腎症の治療剤
JP2011020957A (ja) アルツハイマー病治療薬
MXPA99004460A (en) Combination of dofetilida and a blocking of the calculates
EP0663822A1 (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine
BR112019003201B1 (pt) Composto para uso no tratamento de hipotensão ortostática neurogênica
WO1994014441A1 (en) Use of an enantiomeric dihydropyridine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150325

Termination date: 20200429